MyFinsight
Home
Blog
About
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Loss on debt extinguishment, net
Stock-based compensation
Accrued trade discounts and reba...
Others
Negative Cash Flow Breakdown
Net loss
Inventory
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-31,101
2,234
11,081
621
Depreciation
323
337
335
338
Amortization of intangible assets
2,711
2,710
2,711
2,711
Amortization of premium/discount on investments
-
-
0
0
Amortization of debt discount and debt issuance costs
907
889
866
843
Amortization of operating right-of-use assets
176
163
151
140
Deferred income tax expense (benefit)
-
-
0
0
Stock-based compensation
11,066
4,140
5,272
7,643
Loss on debt extinguishment, net
-30,782
-
0
-
Change in fair value of contingent value rights
-
-
0
0
Other
-
-
0
-
Trade accounts receivable
1,810
5,245
-2,701
703
Prepaid expenses and other current assets
4,489
-145
-1,253
5,153
Inventory
9,502
-851
4,011
4,085
Accounts payable
286
4,250
-1,698
1,996
Other accrued liabilities
-1,512
-1,497
3,704
2,832
Accrued trade discounts and rebates
6,049
6,256
-3,988
11,930
Accrued returns reserve
-125
-246
-247
-566
Increase (decrease) in supply agreement liabilities
-
-
0
-
Operating lease liabilities
-477
-434
-422
-412
Other
4,979
-4,683
2,335
297
Net cash provided by (used in) operating activities
8,263
9,870
20,043
18,432
Capital expenditures
-209
-325
-333
-71
Purchases of investments
-
-
0
0
Sales and maturities of investments
-
-
0
0
Net cash used in investing activities
-209
-325
-333
-71
Proceeds from debt refinancing
-
-
0
0
Payment of debt discount
-
-
0
0
Payments of debt issuance costs
-
-
0
-
Proceeds from issuance of employee stock purchase plan shares
985
-
690
0
Proceeds from exercise of stock options
549
847
584
5,161
Proceeds from issuance of warrants
600
7,333
0
9,167
Repurchase of common stock withheld for taxes
191
17,017
1,540
478
Net cash used in financing activities
1,943
-8,837
-266
13,850
Net increase (decrease) in cash, cash equivalents, and restricted cash
9,997
708
19,444
32,211
Cash, cash equivalents and restricted cash, beginning of year
115,771
115,063
95,619
75,744
Cash, cash equivalents and restricted cash, end of quarter
125,768
-
-
-
Cash paid for interest
10,725
-
-
-
Issuance of common shares in settlement of 2025 convertible debt
0
-
-
-
Exercise of stock options
31
-
-
-
Cash and cash equivalents
121,747
-
-
-
Restricted cash included in other assets
4,021
-
-
-
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows
125,768
115,771
115,063
95,619
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Loss on debt
extinguishment, net
-$30,782K
Proceeds from issuance of
employee stock purchase...
$985K
(18.67%↑ Y/Y)
Proceeds from issuance of
warrants
$600K
Proceeds from exercise of
stock options
$549K
(-90.59%↓ Y/Y)
Stock-based compensation
$11,066K
(17.09%↑ Y/Y)
Accrued trade discounts
and rebates
$6,049K
(-28.37%↓ Y/Y)
Other
$4,979K
(356.37%↑ Y/Y)
Amortization of intangible
assets
$2,711K
(-49.99%↓ Y/Y)
Amortization of debt discount
and debt issuance...
$907K
(-45.49%↓ Y/Y)
Depreciation
$323K
(-49.53%↓ Y/Y)
Accounts payable
$286K
(177.93%↑ Y/Y)
Amortization of operating
right-of-use assets
$176K
(-28.46%↓ Y/Y)
Net cash provided by
(used in) operating...
$8,263K
(183.90%↑ Y/Y)
Net cash used in
financing activities
$1,943K
(188.52%↑ Y/Y)
Canceled cashflow
$49,016K
Canceled cashflow
$191K
Net increase
(decrease) in cash, cash...
$9,997K
(181.04%↑ Y/Y)
Canceled cashflow
$209K
Net loss
-$31,101K
(-178.98%↓ Y/Y)
Inventory
$9,502K
(-15.08%↓ Y/Y)
Prepaid expenses and
other current assets
$4,489K
(348.97%↑ Y/Y)
Trade accounts
receivable
$1,810K
(-85.67%↓ Y/Y)
Other accrued
liabilities
-$1,512K
(53.19%↑ Y/Y)
Operating lease
liabilities
-$477K
(35.71%↑ Y/Y)
Accrued returns reserve
-$125K
(-117.86%↓ Y/Y)
Repurchase of common stock
withheld for taxes
$191K
(-97.84%↓ Y/Y)
Net cash used in
investing activities
-$209K
(28.42%↑ Y/Y)
Capital expenditures
-$209K
(28.42%↑ Y/Y)
Buy us a coffee